Last reviewed · How we verify
DBI-001 Gel
At a glance
| Generic name | DBI-001 Gel |
|---|---|
| Sponsor | DermBiont, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis (PHASE2)
- Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel (PHASE2)
- A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis (PHASE2)
- A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis (PHASE2)
- Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo (PHASE2)
- A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DBI-001 Gel CI brief — competitive landscape report
- DBI-001 Gel updates RSS · CI watch RSS
- DermBiont, Inc. portfolio CI